Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Farnesylacetate, Geranyl
2. Gefarnil
3. Gepharnate
4. Geranyl Farnesylacetate
5. Ulco
1. 51-77-4
2. Geranyl Farnesylacetate
3. Gefanil
4. 3,7-dimethylocta-2,6-dien-1-yl 5,9,13-trimethyltetradeca-4,8,12-trienoate
5. Da-688
6. [(2e)-3,7-dimethylocta-2,6-dienyl] (4e,8e)-5,9,13-trimethyltetradeca-4,8,12-trienoate
7. Da 688
8. 1ise2y6ula
9. Gefarnyl
10. Ncgc00182546-01
11. Gefarnil
12. Trans-3,7-dimethyl-2,6-octadienyl 5,9,13-trimethyl-4,8,12-tetradecatrienoate
13. Dsstox_cid_28562
14. Dsstox_rid_82834
15. Dsstox_gsid_48636
16. Gefarnatum
17. Gefarnato
18. Gefarnatum [inn-latin]
19. Gefarnato [inn-spanish]
20. 5,9,13-trimethyl-4,8,12-tetradecatrienoic Acid 3,7-dimethyl-2,6-octadienyl Ester
21. Cas-51-77-4
22. Gefarnate [inn:ban:jan]
23. 4,8,12-tetradecatrienoic Acid, 5,9,13-trimethyl-, (2e)-3,7-dimethyl-2,6-octadienyl Ester, (4e,8e)-
24. Einecs 200-121-0
25. Unii-1ise2y6ula
26. Osteol
27. Geranyl-farnesylacetate
28. Gefarnate [inn]
29. Gefarnate [jan]
30. Gefarnate [mi]
31. Gefarnate [mart.]
32. Gefarnate [who-dd]
33. (e,e,e)-5,9,13-trimethyl-4,8,12-tetradecatrienoic Acid 3,7-dimethyl-2,6-octadienyl Ester
34. Schembl148495
35. 3,7-dimethylocta-2,6-dienyl 5,9,13-trimethyltetradeca-4,8,12-trienoate
36. Chembl2105085
37. Dtxsid0048636
38. Chebi:31646
39. Hy-b2206
40. Zinc3872668
41. Tox21_112983
42. Mfcd00129086
43. Nsc138947
44. S5477
45. Akos015966756
46. Tox21_112983_1
47. Ac-2134
48. Ccg-268656
49. Cs-7652
50. Db12079
51. Nsc-138947
52. Ncgc00182546-02
53. 111ge003
54. 4,8,12-tetradecatrienoic Acid, 5,9,13-trimethyl-, 3,7-dimethyl-2,6-octadienyl Ester, (e,e,e)-
55. As-15887
56. C75428
57. 051g774
58. Q5530013
59. (4e,8e)-(e)-3,7-dimethylocta-2,6-dien-1-yl 5,9,13-trimethyltetradeca-4,8,12-trienoate
60. 4,8,12-tetradecatrienoic Acid, 5,9,13-trimethyl-, (2e)-3,7-dimethyl-2,6-octadien-1-yl Ester, (4e,8e)-
Molecular Weight | 400.6 g/mol |
---|---|
Molecular Formula | C27H44O2 |
XLogP3 | 9.1 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 15 |
Exact Mass | 400.334130642 g/mol |
Monoisotopic Mass | 400.334130642 g/mol |
Topological Polar Surface Area | 26.3 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 619 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 3 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
A - Alimentary tract and metabolism
A02 - Drugs for acid related disorders
A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
A02BX - Other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
A02BX07 - Gefarnate
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?